Several biotherapeutic agents targeting CD123 have been clinically evaluated against AML, including the CD123-directed recombinant human IL3 fusion toxin Tagraxofusp (SL-401); bispecific antibodies targeting CD123 antigen, such as bispecific T-cell engagers; dual affinity retargeting antibodies; bispecific killer cell engagers; and trispecific killer cell engagers [6,23,24,25,26,27,28,29,30]. This evidence concerns the gene IL3 and acute myeloid leukemia.